<DOC>
	<DOCNO>NCT02156076</DOCNO>
	<brief_summary>The purpose study evaluate effect BMS-919373 atrial fibrillation ( AF ) effect AF burden ( AFB ) , percent time AF , subject paroxysmal AF ( pAF ) administer orally range dos ( 2 mg daily ( QD ) , 5 mg QD , 12 mg QD follow 1-week period load dos 3 mg QD , 8 mg QD 20 mg QD , respectively ) total 4 week . It hypothesize treatment BMS-919373 reduce AF burden compare baseline relative placebo .</brief_summary>
	<brief_title>A Blinded Study Evaluate Effect Atrial Fibrillation Burden Patients With Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description>Primary Purpose : Protocol design assess , use long term non-invasive beat-to-beat monitoring SEEQ Mobile Cardiac Telemetry ( MCT ) system , effect BMS-919373 percent change baseline relative placebo atrial fibrillation burden subject paroxysmal atrial fibrillation .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Signed informed consent Paroxysmal Atrial Fibrillation ( pAF ) available documentation AF reporting symptom within 6 month prior screen Able tolerate withdrawal antiarrhythmic therapy ( rhythm control ) Echocardiographically measure leave ventricular ejection fraction ( LVEF ) ≥40 % , measure within 12 month enrollment Echocardiographically measure leave atrial ( LA ) diameter ≤ 5.0 cm , measure within 12 month enrollment Women childbearing potential AFB &lt; 3 % &gt; 70 % , screen period independently Permanent persistent Atrial Fibrillation Cardioversion within 3 month study drug administration Stroke within 12 month study drug administration TIA within 12 month study drug administration Heart failure NYHA class III great ( symptoms heart failure rest minimal exertion ) Heart failure NYHA class II ( symptoms heart failure routine level exertion ) ejection fraction &lt; 40 % measure echocardiography time within 12 month study enrollment ( i.e . additional ejection fraction measurement ≥ 40 % period counter exclusion ) Valvular heart disease ( include valvular insufficiency stenosis great '' mild '' ) Ablation within 3 month study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>